Formed in 2002, the IPPC began at a time when most privacy programs in the pharmaceutical industry were still at an early stage of development. Nevertheless, companies recognized that data protection issues were growing in public importance and posed complex compliance challenges. The European Union's 1995 Data Protection Directive had been transposed into EU member state laws and enforcement activity was just beginning to pick up. In the United States, health privacy requirements under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) were due to go into effect in 2003 and there were many questions as to how the new regulations would impact pharmaceutical companies. Also that same year, the US Federal Trade Commission (FTC) brought its first data security case.
Today, over 90 countries worldwide have enacted data privacy laws, and data privacy laws continue to spread. Industry leaders have built robust privacy programs, incorporating concepts like Privacy by Design into their internal processes, and continuously adapting programs to meet new requirements and to address evolving business practices. Data privacy officers in these companies wrestle with common concerns around Big Data, Biobanking, Personalized Medicine, Patient Engagement, and Clinical Trials Data Transparency.
The IPPC provides a forum for companies with privacy programs at any stage of development, from leading-edge privacy programs to those just beginning. Member companies share ideas, experiences, and resources, including context-specific tools and guidance.
The vision of the IPPC is to be the leading voice in the global bio-pharmaceutical industry to advance innovative privacy solutions to protect patients, enhance healthcare, and support business enablement.